Advanced searches left 3/3

Dominant - PubMed

Summarized by Plex Scholar
Last Updated: 05 May 2022

* If you want to update the article please login/register

CRISPR/Cas therapeutic strategies for autosomal dominant disorders.

Various CRISPR/Cas methods, including homology-directed repair, base editors, and prime editors, have been able to selectively edit mutant alleles either by inserting these mutations into sgRNA sequences or targeting a novel PAM caused by the mutation mutation. Here, we explore recent advances in CRISPR therapy to treat a variety of autosomal dominant disorders, as well as how they are impacting the landscape for future therapies.

Source link: https://doi.org/10.1172/JCI158287


Variations in leaf water status and drought tolerance of dominant tree species growing in multi-aged tropical forests in Thailand.

We investigated seasonal fluctuations in leaf water status and drought tolerance of dominant tree species in three multi-aged tropical forests ranging from 5 to > 200 years old in Thailand, with similar soil moisture. The trees in young and intermediate forests showed more differences between seasons than the old-growth forest, with trees in young and intermediate forests showing larger differences between seasons and the old-growth forest.

Source link: https://doi.org/10.1038/s41598-022-10988-1


Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant.

Patients that had been previously infected by Omicron BA. 1 have been found to be able to alarmingly reinfect patients that had not been previously infected by Omicron BA. 1. It's likely that BA. 2 or BA. 3 would become a new dominating "variant of worry. " No experimental results have been released about BA. 2 and BA. 3. To properly evaluate BA. 2's and BA. 3's infectivity, vaccine innovation, and antibody resistance, we developed a novel algebraic topology-based deep learning system to quantitatively evaluate BA. 2's and BA. 3's and BA. 3's infectivity, vaccine manufacturing, and antibody resistance. Therefore, we estimate that Omicron BA. 2 is on a path to becoming the next dominant variant. The Omicron BA. 1, BA. 2 will also significantly harm most existing monoclonal antibodies, according to we believe.

Source link: https://doi.org/10.1021/acs.jpclett.2c00469

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions